Skip to content

Vor Biopharma VOR Interest Income

Interest Income at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$229M-31.0%
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
$6.27M+65.3%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$4.1M-37.7%
Design Therapeutics, Inc. logo
Design Therapeutics, Inc.DSGN
$2.07M-23.4%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$4.24M+47.6%
Janux Therapeutics logo
Janux TherapeuticsJANX
$9.85M-13.5%

Other financials

Income statement

See full
Operating income-$35.2M-5.6%
Net income-$219.6M-576%
EPS (diluted)-$5.11+1.9%

Balance sheet

See full
Cash & equivalents$169.9M+239%
Total debt$2.9M-90.5%
Total equity-$150.4M-328%
Total assets$506.7M+364%

Cash flow

See full
Operating cash flow-$38.2M-23.1%
CapEx$48.0K-79.2%
Free cash flow-$38.3M-22.4%

Valuation

See full
Market cap$784.61M+2,513%
Enterprise value$617.68M+5,639%

Returns & leverage

See full
Return on equity-125.4%+671pp
Debt / equity0.5×+0.2×
Current ratio31.1×+27.3×

Where this comes from

Reported directly by Vor Biopharma in its filing.

Tagged under the XBRL concept us-gaap:InvestmentIncomeInterest.

The official record: Vor Biopharma’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vor Biopharma's interest income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Vor Biopharma's interest income?
Vor Biopharma (VOR) reported interest income of $3.94M in Q1 2026.
How has Vor Biopharma's interest income changed year-over-year?
Vor Biopharma's interest income increased by 388.8% year-over-year, from $805K to $3.94M.
What is the long-term trend for Vor Biopharma's interest income?
Over 4 years (2021 to 2025), Vor Biopharma's interest income has grown at a 165.0% compound annual growth rate (CAGR), from $119K to $5.87M.
What does interest income mean?
Income earned from interest-bearing assets including cash deposits, money market funds, treasury securities, corporate bonds, and customer financing receivables.